AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Pharm Country

China Coronavirus Update: Continued Spread, Run on Antivirals and Facemasks, Baby Diagnosed

The most recent figure for the China coronavirus outbreak is 28,018 confirmed cases with 563 deaths in China. Chinese health authorities indicate 19 foreigners have been infected by the virus. There are reports that a Chinese newborn is the youngest person to become infected. The infant was diagnosed 30 hours after birth, apparently having gotten it from the mother.

February 6, 2020

4 min read

Mark Terry

BioMidwest

AbbVie’s HIV Drug Aluvia Seen as Potential Treatment for Coronavirus

The Chinese government is turning to a drug developed by AbbVie for HIV patients as a potential treatment for the outbreak.

January 27, 2020

2 min read

Alex Keown

Deals

Allergan and AbbVie Sell Assets, Inching Closer to Completing Merger

As AbbVie and Allergan near completion of the $63 billion merger, the two companies are shedding some assets in order to meet demands of regulators over concerns of a monopoly.

January 27, 2020

3 min read

Alex Keown

Job Trends

Clinical Catch-Up: January 13-17

There were plenty of clinical trial announcements this week. Here’s a look.

January 17, 2020

7 min read

Mark Terry

Drug Development

AbbVie’s Skyrizi Beats Out Novartis’ Cosentyx in Plaque Psoriasis

AbbVie reported that its Skyrizi met both primary and all ranked secondary endpoints in its Phase III trial that went head-to-head with Novartis’ Cosentyx in plaque psoriasis.

January 14, 2020

3 min read

Mark Terry

Deals

M&A for 2019 was Big; Will 2020 Be Even Bigger?

Consulting firm EY released its annual report on mergers and acquisitions (M&A) to coincide with the JP Morgan Healthcare conference this week. For 2019, EY indicates there were $357 billion in life science deals, an “all-time record,” surpassing the previous high in 2014.

January 13, 2020

4 min read

Mark Terry

Business

AbbVie Sets up Allergan Aesthetics Ahead of Finalizing its $63 Billion Acquisition

While Allergan and AbbVie prepare to complete their $63 billion merger later this year, plans are being laid out for a new, stand-alone company called Allergan Aesthetics that will include Botox as a tent pole.

January 9, 2020

3 min read

Alex Keown

Job Trends

Top Biopharma M&As in 2019

The year was marked by mergers and acquisitions both big and small. Although not comprehensive, here’s a look at some of the top deals for 2019.

December 30, 2019

9 min read

Mark Terry

Business

AbbVie and Scripps Research Enter Research Partnership in Cancer, Immunology, Neurology and Fibrosis

Under the terms of the deal, Scripps will run preclinical R&D, and in some cases, Phase I clinical trials. AbbVie will have an exclusive option to continue development and possible commercialization activities.

December 9, 2019

4 min read

Mark Terry

JOBS